Home » Stocks » NAVB

Navidea Biopharmaceuticals, Inc. (NAVB)

Stock Price: $2.36 USD 0.00 (0.00%)
Updated November 23, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 62.98M
Revenue (ttm) 815,061
Net Income (ttm) -11.15M
Shares Out 26.69M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $2.36
Previous Close $2.36
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.41
Day's Range 2.33 - 2.44
Day's Volume 130,432
52-Week Range 0.63 - 5.36

More Stats

Market Cap 62.98M
Enterprise Value 60.29M
Earnings Date (est) Mar 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 26.69M
Float 18.36M
EPS (basic) -0.51
EPS (diluted) -0.51
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 189,054
Short Ratio 2.61
Short % of Float 1.03%
Beta 2.15
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 77.27
PB Ratio 4.40
Revenue 815,061
Operating Income -10.68M
Net Income -11.15M
Free Cash Flow -8.48M
Net Cash 2.69M
Net Cash / Share 0.10
Gross Margin 79.89%
Operating Margin -1,310.66%
Profit Margin -1,368.50%
FCF Margin -1,040.38%
ROA -123.44%
ROE -2,639.77%
ROIC -5,894.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.50*
(217.80% upside)
Low
7.00
Current: $2.36
High
8.00
Target: 7.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.661.171.814.973.016.271.130.080.600.62
Revenue Growth-43.74%-35.41%-63.58%64.99%-51.98%454.99%1335.94%-86.83%-3.18%-
Gross Profit0.651.071.814.913.014.690.800.080.600.62
Operating Income-10.96-10.85-13.88-10.15-18.44-27.63-38.44-27.99-24.10-12.68
Net Income-10.95-16.1174.95-14.31-27.56-35.73-42.70-29.165.61-49.96
Shares Outstanding14.398.538.087.777.567.446.094.954.534.04
Earnings Per Share-0.76-1.899.00-1.80-3.60-4.80-7.00-5.801.20-14.40
Operating Cash Flow-9.354.2859.083.56-19.08-29.13-35.61-23.92-16.01-5.17
Capital Expenditures0.03-0.05-0.030.04--1.11-1.24-0.66-0.18-0.37
Free Cash Flow-9.334.2359.053.60-19.08-30.24-36.85-24.59-16.19-5.54
Cash & Equivalents1.054.284.596.547.175.4832.949.1228.646.42
Total Debt1.070.322.3561.6061.0833.8327.679.696.460.06
Net Cash / Debt-0.023.962.24-55.06-53.91-28.355.27-0.5722.196.36
Assets4.157.0220.7812.4614.9611.8340.3211.9731.1910.86
Liabilities5.034.618.7380.1368.8041.6344.3313.3810.066.73
Book Value-1.611.7411.38-68.14-54.31-29.80-4.01-1.4121.134.13
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Navidea Biopharmaceuticals, Inc.
Country United States
Employees 13
CEO Jed Andrew Latkin

Stock Information

Ticker Symbol NAVB
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: NAVB
IPO Date November 10, 1992

Description

Navidea Biopharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.